Jane E Brumbaugh1, Edward F Bell2, Shawn C Hirsch3, Emma G Crenshaw3, Sara B DeMauro4, Ira S Adams-Chapman5, Jean R Lowe6, Girija Natarajan7, Myra H Wyckoff8, Betty R Vohr9, Tarah T Colaizy10, Heidi M Harmon10, Kristi L Watterberg6, Susan R Hintz11. 1. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Pediatrics, University of Iowa, Iowa City, IA, USA. edward-bell@uiowa.edu. 3. Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA. 4. Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Pediatrics, Emory University, Atlanta, GA, USA. 6. Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA. 7. Department of Pediatrics, Wayne State University, Detroit, MI, USA. 8. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 9. Department of Pediatrics, Brown University, Providence, RI, USA. 10. Department of Pediatrics, University of Iowa, Iowa City, IA, USA. 11. Department of Pediatrics, Stanford University, Palo Alto, CA, USA.
Abstract
BACKGROUND: Severe retinopathy of prematurity (ROP) is associated with adverse outcomes. Relationships between milder ROP and outcomes have not been defined. We hypothesized that children with ROP stage ≤3 who did not receive ophthalmologic intervention would have worse motor, cognitive, and language skills and more vision abnormalities than children without ROP. METHODS: This was a secondary analysis of a randomized trial evaluating the effects of myo-inositol on ROP in the NICHD Neonatal Research Network. Primary outcomes were Bayley Scales of Infant Development composite scores; secondary outcomes included behavioral difficulties and ophthalmologic measures. Outcomes were compared using adjusted linear or modified Poisson models. RESULTS: Of 506 children, 173 (34%) had no ROP, 262 (52%) had ROP stage ≤3 without intervention, and 71 (14%) had ROP with intervention. There was no difference in motor, cognitive, or language scores between children with ROP stage ≤3 without intervention and children without ROP. Children with ROP stage ≤3 without intervention had a higher rate of strabismus compared to children without ROP (p = 0.040). CONCLUSION: Children with ROP stage ≤3 without intervention did not have adverse neurodevelopmental outcomes at 2 years' corrected age compared to children without ROP but did have an increased incidence of strabismus. IMPACT: This study addresses a gap in the literature regarding the relationship between milder forms of retinopathy of prematurity (ROP) that regress without intervention and neurodevelopment and vision outcomes. Children with a history of ROP stage ≤3 without intervention have similar neurodevelopmental outcomes at 2 years' corrected age as children born extremely preterm without a history of ROP and better outcomes than children with a history of ROP with ophthalmologic intervention. Counseling about likely neurodevelopment and vision outcomes for children born extremely preterm with a history of ROP may be tailored based on the severity of ROP. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: Inositol to Reduce Retinopathy of Prematurity Trial: NCT01954082.
BACKGROUND: Severe retinopathy of prematurity (ROP) is associated with adverse outcomes. Relationships between milder ROP and outcomes have not been defined. We hypothesized that children with ROP stage ≤3 who did not receive ophthalmologic intervention would have worse motor, cognitive, and language skills and more vision abnormalities than children without ROP. METHODS: This was a secondary analysis of a randomized trial evaluating the effects of myo-inositol on ROP in the NICHD Neonatal Research Network. Primary outcomes were Bayley Scales of Infant Development composite scores; secondary outcomes included behavioral difficulties and ophthalmologic measures. Outcomes were compared using adjusted linear or modified Poisson models. RESULTS: Of 506 children, 173 (34%) had no ROP, 262 (52%) had ROP stage ≤3 without intervention, and 71 (14%) had ROP with intervention. There was no difference in motor, cognitive, or language scores between children with ROP stage ≤3 without intervention and children without ROP. Children with ROP stage ≤3 without intervention had a higher rate of strabismus compared to children without ROP (p = 0.040). CONCLUSION: Children with ROP stage ≤3 without intervention did not have adverse neurodevelopmental outcomes at 2 years' corrected age compared to children without ROP but did have an increased incidence of strabismus. IMPACT: This study addresses a gap in the literature regarding the relationship between milder forms of retinopathy of prematurity (ROP) that regress without intervention and neurodevelopment and vision outcomes. Children with a history of ROP stage ≤3 without intervention have similar neurodevelopmental outcomes at 2 years' corrected age as children born extremely preterm without a history of ROP and better outcomes than children with a history of ROP with ophthalmologic intervention. Counseling about likely neurodevelopment and vision outcomes for children born extremely preterm with a history of ROP may be tailored based on the severity of ROP. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: Inositol to Reduce Retinopathy of Prematurity Trial: NCT01954082.
Authors: Earl A Palmer; Robert J Hardy; Velma Dobson; Dale L Phelps; Graham E Quinn; C Gail Summers; Carol P Krom; Betty Tung Journal: Arch Ophthalmol Date: 2005-03
Authors: Elizabeth N Allred; Antonio Capone; Anthony Fraioli; Olaf Dammann; Patrick Droste; Jay Duker; Robert Gise; Karl Kuban; Alan Leviton; T Michael O'Shea; Nigel Paneth; Robert Petersen; Michael Trese; Kathleen Stoessel; Deborah Vanderveen; David K Wallace; Grey Weaver Journal: J AAPOS Date: 2014-06 Impact factor: 1.220
Authors: Gerd E Holmström; Karin Källen; Ann Hellström; Peter G Jakobsson; Fredrik Serenius; Karin Stjernqvist; Kristina Tornqvist Journal: JAMA Ophthalmol Date: 2014-02 Impact factor: 7.389
Authors: M E Msall; D L Phelps; K M DiGaudio; V Dobson; B Tung; R E McClead; G E Quinn; J D Reynolds; R J Hardy; E A Palmer Journal: Pediatrics Date: 2000-11 Impact factor: 7.124
Authors: Danielle S Costa; Débora M Miranda; Alice C Burnett; Lex W Doyle; Jeanie L Y Cheong; Peter J Anderson Journal: Pediatrics Date: 2017-09 Impact factor: 7.124
Authors: Kristbjörg Sveinsdóttir; David Ley; Holger Hövel; Vineta Fellman; Petra S Hüppi; Lois E H Smith; Ann Hellström; Ingrid Hansen Pupp Journal: Neonatology Date: 2018-04-12 Impact factor: 4.035